Effects of Factor Xa on the expression of proteins in femoral arteries from type-2 diabetic patients

A J López-Farré¹, P Rodriguez-Sierra¹, J Modrego¹, A Segura³, N Martin-Palacios¹, A M Saiz², J J Zamorano-León¹, J Duarte⁴, J Serrano² and G Moñux¹


Running head: Factor Xa changes metabolism in diabetic arteries

Word count: 4369

Number of tables: 4

Number of figures: 5

Correspondence to: Guillermo Moñux

Vascular Surgery Department
Hospital Clínico San Carlos
C/ Profesor Martín Lagos s/n
Telephone number: +34913303882
Fax number: 913303692
Madrid 28040, Spain
e-mail: lcarinv.hcsc@salud.madrid.org

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.12469

This article is protected by copyright. All rights reserved.
SUMMARY

Aim: Further to its pivotal role in hemostasis, FXa promotes effects on the vascular wall. The purpose of the study was to evaluate if FXa modifies the expression level of energy metabolism and oxidative stress-related proteins in femoral arteries obtained from type-2 diabetic patients with end-stage vasculopathy. Methods: Femoral arteries were obtained from 12 type-2 diabetic patients underwent to leg amputation. Segments from the femoral arteries were in vitro incubated alone and in the presence of 25 nmol/L FXa and 25 nmol/L FXa+ 50 nmol/L Rivaroxaban. Results: In the femoral arteries, FXa increased triosephosphate isomerase and glyceraldehyde-3-phosphate dehydrogenase isotype 1 expression but decreased pyruvate dehydrogenase expression. These facts were accompanied by an increased content of acetyl-CoA. Aconitase activity was reduced in FXa-incubated femoral arteries as compared with control. Moreover, FXa increased the protein expression level of oxidative stress-related proteins that was accompanied by an increased malonyldialdehyde arterial content. The FXa inhibitor, Rivaroxaban, failed to prevent the reduced expression of pyruvate dehydrogenase induced by FXa but reduced acetyl-CoA content and reverted the decreased aconitase activity observed with FXa alone. Rivaroxaban + FXa but not FXa alone increased the expression level of carnitine palmitoyltransferase I and II, two mitochondrial long-chain fatty acid transporters. Rivaroxaban also prevented the increased expression of oxidative stress-related proteins induced by FXa alone. Conclusions: In isolated femoral arteries from type-2 diabetic patients with end-stage vasculopathy, FXa promoted disruption of the aerobic mitochondrial metabolism. Rivaroxaban prevented such effects and even seem to favour long-chain fatty acid transport into mitochondria.
**Keywords:** Energy metabolism, Factor Xa, Femoral arteries, Oxidative stress, Protein expression

<table>
<thead>
<tr>
<th>What is Known about this topic?</th>
<th>What does this paper add?</th>
</tr>
</thead>
<tbody>
<tr>
<td>- FXa modifies the vascular wall that suggests the FXa as modulator of vascular function.</td>
<td>- FXa stimulates the glycolytic pathway in diabetic arteries but non to pyruvate anaerobic catabolism.</td>
</tr>
<tr>
<td>- Patients with type-2 diabetes mellitus have increased risk of cardiovascular events associated with thrombotic and pro-coagulant conditions.</td>
<td>- There is no involvement of long-chain fatty acid beta oxidation as alternative source to increase acetyl-CoA in FXa-incubated arteries.</td>
</tr>
<tr>
<td>- In diabetes, abnormalities in vascular energy metabolism contribute to vascular dysfunction and higher risk of cardiovascular events.</td>
<td>- FXa changes the expression level of glucose oxidation-related proteins suggesting disruption of mitochondrial metabolism.</td>
</tr>
</tbody>
</table>
INTRODUCTION

During thrombosis, the vascular wall is exposed to clotting factors, including the procoagulant protease factor Xa (FXa). FXa is critical convergence point for the intrinsic and extrinsic coagulation pathways. FXa is produced from factor X and catalyze the conversion of pro-thrombin into thrombin during blood coagulation [1].

Further to its key function as clotting enzyme, FXa also produces effects on the vascular wall suggesting the involvement of FXa as modulator of vascular function. In this regard, and as example, systemic administration of FXa to anesthetized rats caused a hypotensive response associated with the release of nitric oxide from the isolated rat aortic rings [2,3]. Moreover, in cultured endothelial cells FXa reduced the intracellular calcium transients and stimulated cell proliferation and pro-inflammatory cytokines production [4,5,6].

Patients with type-2 diabetes mellitus have increased risk of cardiovascular events associated with thrombotic and pro-coagulant conditions [7]. In this regard, data have shown that diabetic patients with vascular complications are a diabetic subgroup of patients with increased risk of coagulation disorders and fibrinolysis [8]. In this regard, the vascular wall of diabetic patients with end-stage vasculopathy has higher risk to increase platelet activation. Interestingly, it has been demonstrated that platelets from both experimental diabetic animals and diabetic patients are important source for FXa generation, which may contribute to increase the local concentration of FXa, enhancing the exposition of the diabetic vascular wall to FXa during thrombosis [9].

The vascular function is a complex processes that it is dependent of several molecular mechanisms and among them vascular energetic metabolism has a relevant role [10]. The arterial wall is supplied with oxygen and nutrients and aerobic glycolysis is considered characteristic of its physiological metabolism [11]. In this regard, it is
known that in diabetic patients, abnormalities in vascular energy metabolism contribute to vascular dysfunction and, therefore, to higher risk of cardiovascular events [12].

Oxidative stress is also closely associated with disturbed coagulation [13]. Moreover, a close relationship between energy metabolism and oxidative stress has been also postulated. In this regard, mitochondria are not only key in aerobic metabolism but it is also the major site of reactive oxygen species (ROS) production. Several evidences have associated mitochondrial dysfunction with type-2 diabetes mellitus [14,15,16]. However, in our knowledge, oxidative actions of FXa has only been previously reported in human smooth muscle cells from saphenous veins but was not yet explored in the arterial wall of diabetic patients [17].

Therefore, trying to resemble a coagulating situation, where probably FXa concentration should be locally increased, our aim was to determine if exogenous addition of FXa to femoral arteries from patients with type-2 diabetes mellitus and end-stage vasculopathy could modify the expression level of proteins associated with glycolytic metabolism and/or with oxidative stress.

**METHODS**

**Collection of femoral arteries and in vitro incubations**

Femoral arterial segments were obtained from 12 patients diagnosed of type-2 diabetes mellitus undergoing leg amputations by thrombosis. Type-2 diabetes was defined according to the Clinical guidelines Task Force from the International Diabetes Federation [18]. Patients were excluded if they were under anticoagulant and/or antiplatelet treatment 10 days before surgery or the cause of leg amputation was related to infectious disease i.e. osteomyelitis and phlegmon. The investigation was developed
conforms to the principles outlined in the Declaration of Helsinki. All subjects gave fully informed consent and the Institutional Ethic Committee approved the study.

Femoral artery was carefully isolated, washed with serum saline and cut into portions (aprox. 5 mm each). Each portion was incubated in RPMI medium containing 1% fetal calf serum, 5 mmol/L glutamine, 0.01 mmol/L L-arginine, 2x10^{-5} μg/L streptomycin and 2x10^{-5} U/L penicillin. All the procedures were performed under sterile conditions.

From each femoral artery segments were incubated in triplicated form as follow: a) none (control); b) 25 nmol/L FXa and c) 25 nmol/L FXa + Rivaroxaban (50 nmol/L), an specific reversible inhibitor of FXa activity [19]. Rivaroxaban was added to the incubation medium 5 min before FXa.

The used FXa concentration was chosen according to previous in vitro experiments that demonstrated stimulation of pro-collagen production and induction of fibroblasts proliferation for this FXa concentration [19]. Rivaroxaban (Bay 59-7939) was purchased by Bayer Health Care AG and the chosen concentration was based on previous studies that demonstrated that such Rivaroxaban concentration fully inhibited FXa activity [20]. Furthermore, the Rivaroxaban concentration used in the present experiments is clinically relevant [21,22]. In vitro incubations were follow up for 18 hours and, after that, the femoral arterial segments were collected and stored at -80º C until the molecular determinations were performed.

Two-dimensional (2-DE) electrophoresis and mass spectrometry (MS) analysis.

Femoral arterial samples were homogenized with an Ultra-Turrax T8 IKA-Werke homogenized in a buffer containing 8 mol/L urea, 2% CHAPS w/v, 40 mmol/L dithiothreitol, 0.2% Bio-LyteTH ampholyte (Bio-Rad) and 0.01% W/V bromophenol
blue. After incubation in a wheel revolving for 12 hours at 4º C, the homogenate tissues were centrifuged at 10,000 g for 10 min and the supernatant stored at -80ºC until further analysis. Protein determination was performed using bicinchoninic acid reagent (Pierce). Before analysis, samples were submitted to cleanup for isoelectric focusing and 2-DE electrophoresis using a commercial kit, ReadyPrep 2-D Cleanup Kit (BioRad, USA) following the manufacturer instruction. 250 µg of total protein was then loaded onto each gel on immobilized gradient IPG strips (pH 3-10) and isoelectric focusing was performed using a Protean IEF cell system (Bio-Rad laboratories) as reported [23].

In the second dimension, the proteins from femoral arteries were resolved on 10% SDS-PAGE gels using a Protean II XL system (Bio-Rad laboratories) as reported [24]. After electrophoresis, the gels were fixed and silver stained, following manufacturer’s recommendations using a Silver Stain Plus Kit (Bio-Rad laboratories). The gels were then scanned using a UMAX POWERLOOK III Scanner operated by the software Magic Scan V 4.5 and the image analysis was performed using Quantity One 4.2.3 (Bio-Rad Labs). Each spot intensity volume was processed by background subtraction.

For MS, spots were extracted from silver-stained 2-DE gels and digested with sequence-grade modified trypsin (Promega, Madison, WI) as reported [25]. Samples were analyzed using a 4700 Proteomic Analyzer (Applied Biosystem) operated in reflector positive mode. The data generated from spectra were used to identify proteins by peptide mass finger printing, using the MASCOT program and comparing with Mascot database 1.9 (http://www.matrixscience.com). As mentioned in previous works [24,25], MS identifications were accepted based on a tripartite evaluation that takes into account significant molecular weight search (worse) scores, spectrum annotation and observed versus expected migration on 2-DE gels.
Western blot analysis

Protein expression levels of triosephosphate isomerase, pyruvate dehydrogenase, lactate dehydrogenase, carnitine palmitoyltransferase (CPT) I and II (CPT-I and CPT-II) and the gp91-phox, p47-phox and p67-phox subunits of NADPH oxidase was analyzed by Western blot. In brief, the homogenized vascular segments were solubilized in Laemml buffer containing 2-mercaptoethanol. The obtained proteins were separated on denaturing SDS-PAGE 15% (w/v) polyacrylamide gels. Equal amount of proteins (20 μg/lane), estimated by bicinchoninic acid reagent (Pierce), was loaded. Proteins were blotted onto nitrocellulose (Immobilion-P; Millipore) and the blots were blocked overnight at 4ºC with 5 % (w/v) non-fat dry milk. Membranes were then incubated with different antibodies against each of the above-mentioned proteins. For this purpose, triosephosphate isomerase was determined using a polyclonal antibody (TIM (FL-249); sc-30145, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, dilution 1:500). Lactate dehydrogenase was determined using a monoclonal antibody (sc-133123 Santa Cruz Biotechnology, dilution 1:100). Pyruvate dehydrogenase was determined by using a polyclonal antibody (PDK1 sc-7140 dilution 1:1000, Santa Cruz Biotechnology Inc USA). CPT-I and CPT-II and gp91-phox NADPH were determined using polyclonal antibodies at dilution 1:1000 purchased from Santa Cruz Biotechnology Inc (sc-20670, sc20526 and sc-5827 respectively). The cytosolic NADPH oxidase gp47-phox and gp67-phox subunits were determined using polyclonal antibodies at dilution 1:1500 purchased from Santa Cruz Biotechnology Inc (sc-14015 and sc-7663 respectively). The same samples were also incubated with a monoclonal anti-β-actin antibody as loading control. After overnight incubation at 4ºC, nitrocellulose membranes were washed twice and incubated with a peroxidase-conjugated anti-goat IgG antibody (for pyruvate dehydrogenase, CPT-II, and the gp91-phox and gp67-phox NADPH oxidase
isotypes), a peroxidase-conjugated anti-rabbit IgG antibody (for triosephosphate isomerase, CPT-I and p47-phox NADPH oxidase) and with an anti-mouse IgG antibody (for lactate dehydrogenase and β-actin), and developed with enhancing chemoluminiscence reagents (ECL; GE Healthcare, Little Chalfont Buckinghamshire, UK).

**Determination of lactate, acetyl-Coenzyme A (CoA) and malonyldialdehyde (MDA) content and aconitase activity in the femoral arteries**

The content of lactate in the human aortic samples was determined using a lactate assay kits (K607-100; BioVision Incorporated CA,USA) following the manufacturer’s instructions.

In the femoral arteries, the content of acetyl-CoA was determined using and double-antibody sandwhich enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Qayee Biotechnology Co., Shanghai, China). MDA content in the femoral arteries was also determined by enzyme immunoassay technique using a commercial kit (Cloud-Clone Corporation, USA) following the manufacturer’s instructions.

Aconitase activity was determined using a commercial colorimetric assay kit (BioVision Incorporated) following the manufacturer’s instructions.

To determine the content of lactate, acetyl-CoA and MDA content and the aconitase activity in the femoral arteries, 80 µg of each homogenized femoral artery was used.
Statistical analysis.

Results are expressed as mean ± EEM. Wilcoxon’s test was used to determine statistical significances. To control the potential antioxidant effects of statin treatment and multivariate linear regression analyses was performed. The dependent variable was the level of MDA content and the level of expression of the oxidative-related proteins in the femoral arteries; the fixed factor was the sample type (control, FXa- and FXa+Rivaroxaban-incubated arteries) and statin treatment was used as covariant. A p-value<0.05 was considered statistically significant.

RESULTS

Effect of FXa in the level of expression of glycolytic-related proteins in the femoral arterial wall.

Table 1 shows the clinical features of the included patients. All the included patients showed diabetes mellitus and they were not undergone to any antiplatelet and/or anticoagulant treatments from at least 10 days before the femoral artery was obtained. At inclusion, a number of patients were under statin treatment.

In the proteomic analysis the studied spots were those at least expressed in 80% of the 2DE gels within each experiment group. MS analysis was only performed in spots in which statistical differences between control and FXa-incubated arteries were observed. Table 2 shows the MS features of such spots identified in the femoral arteries. In FXa-incubated femoral arteries the protein expression of two identified triosephosphate isomerase isoforms was increased as compared with those arteries incubated under control conditions (Table 3). This greater expression observed in the
FXa-incubated femoral arteries was further confirmed by Western blot experiments (Figures 1a and 1b). Moreover, the protein expression of glyceraldehyde-3-phosphate dehydrogenase isoform 1 was also higher in FXa-incubated femoral arteries than in control (Table 3).

The proteomic analysis also revealed that lactate dehydrogenase expression was similar in FXa-incubated femoral arterial segments than in control (Table 3). It was also confirmed by Western-blot analysis (Figures 1A and 1B). In addition, lactate content in the FXa-incubated femoral arteries was also similar to control (lactate content in nmol/mg protein: control: 17.04 ± 1.42; FXa: 15.92 ± 2.31; pNS).

Pyruvate dehydrogenase expression (enzyme involved in conversion of pyruvate into acetyl-CoA) determined by Western blot was significantly reduced in FXa-incubated arteries with respect to control (Figures 1A and 1B). However, acetyl-CoA content in the FXa-incubated femoral arteries was greater than that observed in control conditions (acetyl-CoA content in pmol/mg protein: control: 2.02 ± 0.39, FXa-incubated arteries: 5.20 ± 0.67 p<0.05).

Two isoforms of the mitochondrial precursors of acyl-CoA dehydrogenase, enzyme involved in long-chain fatty acids beta-oxidation, were also identified in the femoral arterial wall, although the protein expression level of none of them were changed by FXa (Table 3). Moreover, the protein expression level of CPT-I and CPT-II was also determined by Western blotting and they were not significantly different between FXa-incubated and control arteries (Figures 1A and 1B).

In the tricarboxylic acid cycle, citrate is converted by aconitase into isocitrate. In the femoral arteries, FXa significantly reduced aconitase activity as compared with control (Figure 2).
The proteomic analysis also showed a higher protein expression level of creatine kinase M chain in FXa-incubated femoral arteries than in control (Table 3). The level of expression of other identified energy metabolism-related proteins was not different between control and FXa-incubated arteries (Table 3).

**Effects of Rivaroxaban on the modifications induced by FXa on the glycolytic metabolism.**

Addition of Rivaroxaban to FXa-incubated femoral arteries reduced the expression level of triosaphosphate isomerase isoforms 1 and 2 with respect to those arteries incubated with FXa alone (Table 3 and Figures 1A and 1B). The protein expression level of glyceraldehyde-3-phosphate dehydrogenase isoform 1 was also decreased in the femoral arteries incubated with Rivaroxaban + FXa as compared with FXa alone and it was not statistically different with respect to control (Table 3).

In the diabetic femoral arterial wall, addition of Rivaroxaban to FXa did not modify either lactate dehydrogenase expression and lactate content as compared with control and with FXa-incubated arteries (lactate content in Rivaroxaban+FXa-incubated femoral arteries: 18.52 ±02.89 nmol/mg protein).

In Rivaroxaban+FXa-incubated femoral arteries, pyruvate dehydrogenase expression remained reduced with respect to control and even this reduction tended to be more marked than that observed with FXa alone (Figures 1A and 1B). Moreover, acetyl-CoA content in the Rivaroxaban+FXa-incubated femoral arteries was similar to control and significantly reduced with respect to FXa-incubated arteries (acetyl-CoA content: Rivaroxaban+FXa: 1.39 ± 0.28 pmol/mg arterial protein; p<0.05 with respect to FXa alone).
Protein expression level of CPT-I and CPT-II was significantly increased in FXa+Rivaroxaban-incubated arteries as compared with both FXa-incubated and control arteries (Figures 1A and 1B). In addition, aconitase activity was increased in FXa+Rivaroxaban-incubated arteries with respect to those incubated with FXa alone (Figure 2). Finally, the expression of creatine kinase M chain was reduced in the femoral arteries incubated with Rivaroxaban + FXa as compared with those incubated with FXa alone and it was similar to that found in control arteries (Table 3).

Effects of FXa and Rivaroxaban on the expression of proteins related to oxidative stress

As table 4 shows, FXa apparently increased the protein expression level of glutathione-S-transferase and two aldehyde dehydrogenase isoforms as compared with control. The protein expression level of the mitochondrial gp91-phox NADPH oxidase isotype and the cytosolic gp47-phox and gp67-phox NADPH oxidase isotypes was also significantly higher in FXa-incubated femoral arteries than in control (Figure 3). It was accompanied by an increased content of MDA in the FXa-incubated arteries with respect to control (Figure 4). The differences in MDA content and the protein expression level of the cytosolic and mitochondrial gp-phox NADPH isotypes between FXa-incubated and control arteries remained significantly increased after adjustment by statin treatment, drug with antioxidant properties, suggesting that the effects of FXa on these parameters were independent of the use of statins (Figures 3 and 4). However, neither the protein expression level of S–glutathione transferase nor the two aldehyde dehydrogenase isoforms was different between control and FXa-incubated arteries when in the lineal regression model results were adjusted by statins (Table 4).
Addition of Rivaroxaban to FXa reduced the increased protein expression level of either gp91-, gp47- and gp67-phox NADPH oxidase isotypes induced by FXa alone even when the results were adjusted by statin treatment (Figure 3). MDA content in the femoral arteries was also reduced in FXa+ Rivaroxaban-incubated femoral arteries as compared with those incubated with FXa alone and this difference remained significative after used statin treatment as covariant (Figure 4).

**DISCUSSION**

The present study shows for the first time effects of FXa on the expression of proteins-related to energetic metabolism in human arteries and identified impact upon levels of proteins involved in energy metabolism. The results showed that in femoral arteries from type-2 diabetic patients with end-stage vasculopathy, FXa modified the expression level of proteins involved in glycolytic metabolism. It was accompanied by a significant increased expression of proteins associated with oxidative stress. Moreover, in the diabetic femoral arteries Rivaroxaban, a specific inhibitor of FXa activity, reverted most of the effects elicited by FXa on the energy metabolism and oxidative stress and seems to favour long chain fatty acid transport into the mitochondria.

Glucose metabolism is an important determinant of vascular reactivity [26,27]. The present study shows that in the diabetic femoral arterial wall, the level of expression of two triosephosphate isomerase isoforms, a glycolitic key-step enzyme, was significantly increased by FXa as compared with control. FXa also increased the level of expression of an isoform of another important glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase. Initially, these findings might suggest that FXa stimulated the glycolytic pathway in diabetic arteries.

In the arterial wall, the reported stimulation of different molecular mechanisms
elicited by FXa, i.e. cell proliferation and synthesis of inflammatory mediators, may require an increase energy demand [28,29]. Therefore, despite of the well known abnormal glucose transport in human type-2 diabetes, the possible greater energy demand related to FXa may promote the increase in triosephosphate isomerase expression and glyceraldehyde-3-phosphate dehydrogenase two of the main enzymes that regulate the glycolytic pathway. However, the expression level of pyruvate dehydrogenase, enzyme included in the pyruvate dehydrogenase complex that mediates pyruvate oxidation to yield acetyl-CoA, was reduced in FXa-incubated arteries. This pyruvate dehydrogenase downexpression in FXa-incubated femoral arteries may direct pyruvate into lactate promoting an anaerobic state. However, the anaerobic catabolism of pyruvate seems to be non-affected by FXa since in the femoral arteries neither lactate dehydrogenase expression nor lactate content were changed by FXa.

Apparently, a paradoxical result may be the observation that the acetyl-CoA content increased in FXa-incubated arteries with respect to control since pyruvate dehydrogenase has been downexpressed by FXa. Long-chain fatty acid beta-oxidation is an alternative metabolic pathway to glucose oxidation and also yields acetyl-CoA that then it is catabolized by the tricarboxylic acid cycle. In this regard, circulating levels of free fatty acids have been reported elevated in diabetes because of their excess liberation from adipose tissue and diminished uptake by skeletal muscle [30,31]. However, the expression level of two enzymes, CPTI and CPTII, involved in the mitochondrial fatty acid transport a rate-limiting step in long chain fatty acid oxidation. In addition, the protein expression levels of CPT-I and CPT-II were not modified by FXa. Moreover, protein expression level of two isotypes of the mitochondrial precursors of acyl-CoA dehydrogenase, enzyme involved in fatty acid beta-oxidation, was not changed by FXa. Taken together, these findings seem to diminish the involvement of
long-chain fatty acid beta oxidation as alternative source to increase acetyl-CoA in FXa-incubated arteries.

Another possible cause to increase acetyl-CoA accumulation in FXa-incubated diabetic femoral arteries could be disruption of the energy metabolism downstream to acetyl-CoA. Acetyl-CoA is metabolized throughout the tricarboxylic acid cycle in the mitochondria. In this regard, a reduced tricarboxylic acid cycle flux has been also shown in type-2 diabetic patients [32]. Therefore, in the diabetic femoral wall FXa may increase the dysfunction of the tricarboxylic acid cycle promoting acetyl-CoA accumulation. Accordingly, in FXa-incubated femoral arteries aconitase activity, enzyme that converts citrate to isocitrate in the tricarboxylic acid cycle, was significantly reduced. Moreover, creatine kinase M chain expression was increased by FXa. Creatine kinase M chain maintains elevated ATP levels when other ATP generating sources are not able to support ATP requirements [33], further supporting that probably FXa-incubated arteries may need alternative sources than either glycolysis and long-chain fatty acid beta oxidation to provide ATP to the vascular wall.

Oxidative stress is closely associated not only with energy metabolism and mitochondrial dysfunctionality but also with disturbed coagulation. As example, in hemodialysis patients NADPH oxidase activity was correlated with coagulation priming [34]. Although several evidences have suggested that generation of reactive oxygen species may play an important role in the pathogenesis and complication of diabetes [35,36], less is known about the role of FXa on the oxidative stress in the vascular wall. In this regard, a previous work demonstrated that FXa increased oxidative stress in human vascular smooth muscle cells from saphenous vein [17]. We here showed that in the diabetic femoral arteries, FXa increased the protein expression level of gp 47-phox, 67-phox and gp91-phox NADPH oxidase isotypes, catalytic subunits of cytosolic and
mitochondrial NADPH oxidases, supporting pro-oxidative features for FXa. It was further supported by the fact that in the femoral arteries FXa increased the content of MDA, a sign for lipid peroxidation since it is produced during the attack of free radicals to membrane lipoproteins and polyunsaturated fatty acids [37]. Accordingly, increased circulating MDA levels were previously reported in diabetic patients [38]. Therefore, as speculation, FXa may exacerbate oxidative stress in the vascular wall of diabetic patients that may participate in the vascular damage associated with type 2 diabetes mellitus.

The effect of FXa on the expression of these pro-oxidant enzymes and MDA content in the arteries was not modified after adjusted by statin treatment suggesting that these pro-oxidant effects of FXa also occurred in the presence of statins. However, statin treatment affected the apparent modification elicited by FXa on other oxidative-related proteins such as glutathione-S-transferase, an antioxidant protein [40], and two cytosolic aldehyde dehydrogenase, enzyme that oxidize aldehyde to carboxylic acid. Taken together, these findings may suggest that the presence of statins probably reduced the impact of FXa on the expression of specific oxidative stress-related proteins but not on others.

**Effects of Rivaroxaban on the changes induced by FXa**

Rivaroxaban although prevented most of the effects of FXa on the energetic metabolism; however, failed to modify FXa-induced pyruvate dehydrogenase downexpression. Since Rivaroxaban specifically inhibits FXa activity, it seems to be difficult to explain it. However, Bono F et al previously demonstrated that the catalytic inactivation of FXa suppressed FXa-induced increase in cytosolic free Ca$^{2+}$ but failed to
reduce ligand binding of FXa to affect cell protease receptor-1 (EPR-1) [41]. EPR-1 behaves as cofactor for FXa to catalyze prothrombin activation in the absence of FXa. Interestingly, EPR-1 was reported expressed in endothelial cells [42,43]. Therefore, further experiments are needed to characterize if in the diabetic femoral arteries EPR-1 are coupled to downexpression of pyruvate dehydrogenase mediates by FXa. The fact that addition of Rivaroxaban to FXa increased the expression level of two carnitine palmitoyltransferases, proteins that transport fatty acid into the mitochondria, may suggest that in the diabetic arterial wall Rivaroxaban facilitates the activity of alternative metabolic pathways other than glucose oxidation, such as fatty acid beta oxidation. The common end-product of both fatty acid beta-oxidation and glucose oxidation, acetyl-CoA was reduced in Rivaroxaban+FXa-incubated arteries suggesting that tricarboxylic acid cycle activity was probably improved by Rivaroxaban. It was further supported by the fact that aconitase activity was markedly increased in Rivaroxaban+FXa-incubated femoral arteries as compared with those incubated with FXa alone. Taken together, the increased aconitase activity and the increased expression level of the two mitochondrial fatty acid transporters, CPT-I and CPT-II, support improvement of mitochondrial energetic metabolism by Rivaroxaban.

In the diabetic femoral arteries, Rivaroxaban also prevented the upexpression of oxidative stress-related proteins and prevented the increased arterial MDA content induced by FXa. It is also in accordance with the apparent better mitochondrial functionality observed in the experiments with Rivaroxaban+FXa with respect to those with FXa alone.
Comments and study limitations

At present, some controversial results exist in the available sparse published data about if FXa was increased or not in diabetic patients [44,45]. However, it was postulated that diabetic patients showing vascular complications could be a subgroup of diabetic patients with increased risk of coagulation and fibrinolytic disorders [8]. Moreover, platelets from both experimental diabetic animals and diabetic patients showed higher FXa generation, which additionally it may contribute to greater exposition of the diabetic vascular wall to FXa during thrombosis [9]. Based on these knowledgements, we here only tried to test in vascular wall obtained from diabetic patients with end-stage vasculopathy whether an increased exposition to FXa may modify the protein expression level of energetic metabolism and oxidative-stress-related proteins. Moreover, we must to point out that the here used arterial samples were obtained during leg amputation by thrombosis from diabetic patients with end-stage vasculopathy. It is important to point out that there was not any other practical way to obtain such type of tissues. Therefore, the present findings should be only considered for the type of arterial samples here tested.

An observation extracted from the present findings was that Rivaroxaban might exert additional effects non-related to FXa, since FXa by itself did not modify the expression of CPT-I and CPT-II in the diabetic femoral arteries but it was increased in presence of Rivaroxaban [46]. In this regard, it has been reported the existence of Rivaroxaban-derivated metabolites. Therefore, we can not discard that the observed effect of Rivaroxaban on CPT-I and CPT-II expression could due to Rivaroxaban by itself but also by its identified metabolites. Although it seems to be an interesting observation, at present it is out of the scope of the present study and further experiments are needed to clarify it.
A limitation of the present study is the difficulty to determine the clinical implications of the effects of FXa on the energy metabolism and oxidative stress in the femoral diabetic arteries. The fact that FXa may exert vascular effects further to participate in coagulation should increase the interest for the pharmacological perspectives of the FXa inhibitors. In this regard, it is plausible that incorporation of specific FXa inhibitors, as Rivaroxaban, to the conventional treatment of higher risk cardiovascular patients, as type-2 diabetic patients, may improve prevention of acute vascular events where vascular functionality plays a pivotal role. In this regard, Rivaroxaban reduced ischemic events including mortality across a broad-acute coronary syndrome population in the ATLAS-ACS trial [47].

As conclusion, in isolated femoral arteries from type-2 diabetic patients with end-stage vasculopathy, FXa promoted changes in the expression level of proteins related to glucose oxidation suggesting disruption of mitochondrial metabolisms that it was also accompanied by an increased expression of oxidative stress-related proteins. The better knowledge of the molecular mechanisms trigger by FXa may open new clinical approaches for the use of FXa inhibitors.
ACKNOWLEDGEMENTS

Javier Modrego is staff member of RETICs. José J. Zamorano León is staff member of Comunidad de Madrid (S2010/BMD-2374). We thank Begoña Larrea for secretarial assistance.

FUNDING

This work was supported by Fondo de Investigaciones de la Seguridad Social [Redes temáticas de Investigación Cooperativa (RETICs) RD12/0042/0040], Fondo Europeo de Desarrollo Regional (Fondos FEDER) and Bayer Pharmaceuticals.

CONFLICT OF INTEREST

All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
REFERENCES


LEGENDS OF THE FIGURES

Figure 1.- A: Representative Western blots of triosephosphate isomerase (TPI), lactate dehydrogenase (LDH), pyruvate dehydrogenase (PDH) and carnitine palmitoyltransferase (CPT)-I and CPT-II. The expression of β-actin was used as loading protein control. B: Bar graphs showing the densitometric analysis in arbitrary units (AU) of the entire Western blots. Densitometric values are represented as mean ± SEM. *P <0.05 with respect to control. #P <0.05 with respect to FXa alone.

Figure 2.- Bar graphs show aconitase activity in diabetic femoral arteries incubated in presence and absence of FXa and Rivaroxaban. Results are represented as mean ± SEM. *P <0.05 with respect to control. #P <0.05 with respect to FXa alone.

Figure 3.- Representative Western blots of the mitochondrial gp91-phox NADPH oxidase isotype and the cytosolic gp47-phox and gp67-phox NADPH oxidase isotypes. Bar graphs show the densitometric analysis in arbitrary units (AU) of all the Western blots. The expression of β-actin was used as loading protein control. Densitometric values are represented as mean ± SEM. *P <0.05 with respect to control. #P <0.05 with respect to FXa alone. Statin treatment was used as covariant into the model to give adjusted P values.

Figure 4.- Bar graphs show malondialdehyde content in diabetic femoral arteries incubated in presence and absence of FXa and Rivaroxaban. Results are represented as mean ± SEM. *P <0.05 with respect to control. #P <0.05 with respect to FXa alone. Statin treatment was used as covariant into the model to give adjusted P values.
Table 1. Clinical features of the included type-2 diabetes mellitus patients.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>73.8±2.65</td>
</tr>
<tr>
<td>Male/Female</td>
<td>11/1</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.90±1.62</td>
</tr>
<tr>
<td>Risk factors (%)</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>9/12 (75%)</td>
</tr>
<tr>
<td>Dyslipemia</td>
<td>4/12 (33%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>12/12 (100%)</td>
</tr>
</tbody>
</table>

**Previous history**
- Congestive cardiac failure: 3/12 (25.0%)
- Acute myocardial infarction: 3/12 (25.0%)
- Cerebral infarction: 3/12 (25.0%)

**Pharmacological treatment**
- Statins: 7/12 (58.3%)
- Oral anti-diabetic drugs + diet: 4/12 (33.3%)
- Insulin+diet: 6/12 (50.0%)
- Diet alone: 2/12 (16.6%)

Results are represented as mean ± S.E.M.
Table 2. Proteins identified using mass spectrometry after 2DE electrophoresis sorted according with the metabolic pathways.

<table>
<thead>
<tr>
<th>Metabolic pathways</th>
<th>Protein</th>
<th>Matched peptides</th>
<th>Identification method</th>
<th>Sequence coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aerobic glycolysis</strong></td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>LISWYDNFGYSNR</td>
<td>MS/MS</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Triosephosphate isomerase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Isotype 1</td>
<td>LPADTEVVCAPP TAYIDFAR/ DLGATW VVLGHSER/HIFGESDELIGQKVVF EQT K/TATPQQAQEVHEK/CNVSEGVAQCT R</td>
<td>MS</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>Isotype 2</td>
<td>AIIAGNWKNHTIDESVK/VGAKNHYF EEEKGAFTGEVSLMLEK/ETDQTVNK/E NGVTEEVYSK/LVIAYPEIWAGTGK/A NDFSAIVNYK</td>
<td>MS</td>
<td>34</td>
</tr>
<tr>
<td><strong>Anaerobic glycolysis</strong></td>
<td>L-Lactate dehydrogenase C chain</td>
<td>LIENLIEEDKISQR</td>
<td>MS/MS</td>
<td>4</td>
</tr>
<tr>
<td><strong>Other metabolic pathways</strong></td>
<td>Creatin Kinase M chain</td>
<td>DLFDPQDRHGKPFITDK/GGDDLDPN YVLSSR/GYTLPHCSRI/GKKYVLPI/GI WHNDNKSFLVWVNEEHLRL/FVEILTR /GTGGVDTAAVGA/VDISNADR</td>
<td>MS</td>
<td>25</td>
</tr>
<tr>
<td><strong>Oxidative stress</strong></td>
<td>Aldehyde dehydrogenase</td>
<td>KTFPVNPsTGEVQCVAAGDKEDVDR AVK/YYAOAWDK</td>
<td>MS+MS/MS</td>
<td>7</td>
</tr>
<tr>
<td>Isotype 1</td>
<td>TFTP NTVSTGELWUV AQSKEDV DK/V AFTGSTEVQHLQVAAGISNLK</td>
<td>MS+MS/MS</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** MS: mass spectrometry. MS/MS: Tandem-mass spectrometry.
Table 3. Level of expression energy metabolism-related proteins in the femoral artery.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Control (A.U.)</th>
<th>FXa (A.U.)</th>
<th>FXa + Rivaroxaban (A.U.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fructose 1,6-bisphosphate aldolase</td>
<td>18.32±7.6</td>
<td>19.65±6.43</td>
<td>12.00±4.80</td>
</tr>
<tr>
<td>Triosephosphate isomerase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoform 1</td>
<td>7.80±2.46</td>
<td>13.34±3.68*</td>
<td>6.23±1.79#</td>
</tr>
<tr>
<td>Isoform 2</td>
<td>8.20±3.12</td>
<td>29.75±6.60*</td>
<td>13.55±5.82</td>
</tr>
<tr>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoform 1</td>
<td>8.91±3.12</td>
<td>19.28±5.35*</td>
<td>7.19±2.71#</td>
</tr>
<tr>
<td>Isoform 3</td>
<td>39.08±16.05</td>
<td>33.45±14.79</td>
<td>20.10±13.26</td>
</tr>
<tr>
<td>Phosphoglycerate kinase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoform 1</td>
<td>16.20±4.64</td>
<td>16.00±6.31</td>
<td>18.50±4.24</td>
</tr>
<tr>
<td>Isoform 2</td>
<td>10.88±4.04</td>
<td>9.60±3.23</td>
<td>16.52±4.68</td>
</tr>
<tr>
<td>Phosphoglycerate mutase</td>
<td>12.87±4.21</td>
<td>14.94±9.87</td>
<td>13.73±3.41</td>
</tr>
<tr>
<td>Alpha-enolase</td>
<td>13.78±3.48</td>
<td>13.06±4.84</td>
<td>8.27±1.90</td>
</tr>
<tr>
<td>Gamma enolase</td>
<td>15.48±4.24</td>
<td>16.57±4.15</td>
<td>13.20±3.74</td>
</tr>
<tr>
<td>Pyruvate kinase</td>
<td>15.90±4.05</td>
<td>24.27±5.56</td>
<td>15.07±2.09</td>
</tr>
<tr>
<td>Lactate dehydrogenase</td>
<td>17.20±5.59</td>
<td>16.14±3.77</td>
<td>15.84±4.83</td>
</tr>
<tr>
<td>Aconytate hydratase</td>
<td>12.13±3.46</td>
<td>15.99±3.11</td>
<td>15.35±1.96</td>
</tr>
<tr>
<td>Mitochondrial precursor acyl CoA dehydrogenase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoform 1</td>
<td>6.40±1.91</td>
<td>9.79±3.54</td>
<td>5.79±1.46</td>
</tr>
<tr>
<td>Isoform 2</td>
<td>5.22±1.46</td>
<td>5.39±1.42</td>
<td>4.54±0.84</td>
</tr>
<tr>
<td>Creatin kinase M chain</td>
<td>13.39±4.37</td>
<td>33.96±7.96*</td>
<td>15.16±3.45#</td>
</tr>
</tbody>
</table>

A.U. Arbitrary units. The results are represented as mean ± SEM.* p<0.05 with respect to control. # p<0.05 with respect to FXa alone.
Table 4. Expression level of oxidative stress-related proteins in the femoral artery.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Control (A.U.)</th>
<th>FXa (A.U.)</th>
<th>FXa + Rivaroxaban (A.U.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutathione-S-transferase</td>
<td>56.44±11.57</td>
<td>98.09±8.06</td>
<td>43.49±7.53</td>
</tr>
<tr>
<td>Aldehyde dehydrogenase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoform 1</td>
<td>12.29±3.88</td>
<td>27.66±7.99</td>
<td>15.42±3.33</td>
</tr>
<tr>
<td>Isoform 2</td>
<td>17.14±6.20</td>
<td>31.25±6.99</td>
<td>15.24±4.02</td>
</tr>
</tbody>
</table>

A.U. Arbitrary units. The results are represented as mean ± SEM. Statin treatment was used as covariant into the model to give adjusted P values.
Figure 1 A

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>FXa</th>
<th>FXa + Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPI</td>
<td></td>
<td></td>
<td>54 Kda</td>
</tr>
<tr>
<td>PDH</td>
<td></td>
<td></td>
<td>48 Kda</td>
</tr>
<tr>
<td>LDH</td>
<td></td>
<td></td>
<td>35 Kda</td>
</tr>
<tr>
<td>CPT-I</td>
<td></td>
<td></td>
<td>75 Kda</td>
</tr>
<tr>
<td>CPT-II</td>
<td></td>
<td></td>
<td>67 Kda</td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td>42 Kda</td>
</tr>
</tbody>
</table>
Figure 2

![Bar graph showing aconitase enzyme activity (nmol/min/mg protein) for Control, FXa, and FXa + Rivaroxaban.](bcp_12469_f2)
Figure 3

Gp91-phox NADPH
Control  FXa  FXa + Rivaroxaban
91 Kda

Gp67-phox NADPH
Control  FXa  FXa + Rivaroxaban
59 Kda

Gp47-phox NADPH
Control  FXa  FXa + Rivaroxaban
47 Kda

β-actin
Control  FXa  FXa + Rivaroxaban
42 Kda
**Figure 4**

![Bar graph showing the malondialdehyde content (pmol/μg protein) for Control, FXa, and FXa + Rivaroxaban groups.](bcp_12469_f4)